Clopenthixol

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Clopenthixol
Accession Number
DB13841
Description

Clopenthixol is a thioxanthene with therapeutic actions similar to the phenothiazine antipsychotics. It is an antagonist at D1 and D2 dopamine receptors.

Type
Small Molecule
Groups
Experimental
Structure
Thumb
Weight
Average: 400.97
Monoisotopic: 400.1376123
Chemical Formula
C22H25ClN2OS
Synonyms
  • 4-(3-(2-Chloro-9H-thioxanthen-9-ylidene)propyl)-1-piperazineethanol
  • 4-(3-(2-Chlorothioxanthen-9-ylidene)propyl)-1-piperazineethanol
  • Chlorpenthixol
  • Clopenthixol
  • Clopenthixolum
  • Clopentixol
  • Sordinol
External IDs
  • AY-62021
  • N-746

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Clopenthixol.
AcetophenazineThe risk or severity of adverse effects can be increased when Acetophenazine is combined with Clopenthixol.
AclidiniumClopenthixol may increase the central nervous system depressant (CNS depressant) activities of Aclidinium.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Clopenthixol.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Clopenthixol.
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Clopenthixol.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Clopenthixol.
AlosetronThe risk or severity of adverse effects can be increased when Alosetron is combined with Clopenthixol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Clopenthixol.
AlverineThe risk or severity of adverse effects can be increased when Alverine is combined with Clopenthixol.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Categories

ATC Codes
N05AF02 — Clopenthixol
Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
0A432D932A
CAS number
982-24-1
InChI Key
WFPIAZLQTJBIFN-UHFFFAOYSA-N
InChI
InChI=1S/C22H25ClN2OS/c23-17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)27-22)5-3-9-24-10-12-25(13-11-24)14-15-26/h1-2,4-8,16,26H,3,9-15H2
IUPAC Name
2-{4-[3-(2-chloro-9H-thioxanthen-9-ylidene)propyl]piperazin-1-yl}ethan-1-ol
SMILES
[H]C(CCN1CCN(CCO)CC1)=C1C2=C(SC3=C1C=C(Cl)C=C3)C=CC=C2

References

General References
Not Available
KEGG Drug
D02613
ChemSpider
11945
BindingDB
81491
ChEBI
59115
ChEMBL
CHEMBL3989892
Wikipedia
Clopenthixol

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0026 mg/mLALOGPS
logP4.46ALOGPS
logP4.22ChemAxon
logS-5.2ALOGPS
pKa (Strongest Acidic)15.59ChemAxon
pKa (Strongest Basic)8.03ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area26.71 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity127 m3·mol-1ChemAxon
Polarizability45.29 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on June 23, 2017 14:49 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates